Activation of c-Jun NH2-terminal kinase 1 increases cellular responsiveness to BMP-2 and decreases binding of inhibitory Smad6 to the type 1 BMP receptor

Journal of Bone and Mineral Research

Volumn 26, Issue 5, 2011, Pages 1122-1132

  Liu, Hui ^a   Liu, Yunshan ^a   Viggeswarapu, Manjula ^a   Zheng, Zhaomin ^b   Titus, Louisa ^a   Boden, Scott D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

BMP; C JUN NH2 TERMINAL KINASE (JNK); MITOGEN ACTIVATED PROTEIN KINASE (MAPK); OSTEOGENESIS; SMAD

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR; SMAD1 PROTEIN; SMAD6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PLURIPOTENT STEM CELL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; ENZYME ACTIVATION; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; OSTEOBLASTS; PHOSPHORYLATION; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SMAD1 PROTEIN; SMAD6 PROTEIN; TRANSCRIPTION, GENETIC;

EID: 79955631436     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.296     Document Type: Article

References (37)

1. Kingsley DM., The TGF-β superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994; 8: 133-146.
2. Xiao YT, Xiang LX, Shao JZ., Bone morphogenetic protein. Biochem Biophys Res Commun. 2007; 362: 550-553.
3. Luu HH, Song WX, Luo X, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res. 2007; 25: 665-677. (Pubitemid 46730519)
4. Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR., Bone morphogenetic protein 2: biology and applications. Clin Orthop Relat Res. 1996; 324: 39-46. (Pubitemid 26071749)
5. Boden SD, Kang J, Sandhu H, Heller JG., Use of recombinant human bone morphogenetic protein 2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial [2002 Volvo Award in clinical studies]. Spine (Phila). 2002; 27: 2662-2673. (Pubitemid 35425320)
6. Rihn JA, Gates C, Glassman SD, Phillips FM, Schwender JD, Albert TJ., The use of bone morphogenetic protein in lumbar spine surgery. J Bone Joint Surg Am. 2008; 90: 2014-2025.
7. Smoljanovic T, Bojanic I, Delimar D., Adverse effects of posterior lumbar interbody fusion using rhBMP-2. Eur Spine J. 2009; 18: 920-923 author reply 924.
8. Miyazono K., Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone. 1999; 25: 91-93. (Pubitemid 29322068)
9. Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI, Knaus P., Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol Biol Cell. 2000; 11: 1023-1035. (Pubitemid 30159319)
10. Ross S, Hill CS., How the Smads regulate transcription. Int J Biochem Cell Biol. 2008; 40: 383-408. (Pubitemid 351241229)
11. Hayashi H, Abdollah S, Qiu Y, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell. 1997; 89: 1165-1173. (Pubitemid 127678749)
12. Imamura T, Takase M, Nishihara A, et al. Smad6 inhibits signalling by the TGF-beta superfamily. Nature. 1997; 389: 622-626. (Pubitemid 27446182)
13. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A., Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev. 1998; 12: 186-197. (Pubitemid 28060449)
14. Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K., Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J Biol Chem. 2007; 282: 20603-20611. (Pubitemid 47100044)
15. Wu X, Shi W, Cao X., Multiplicity of BMP signaling in skeletal development. Ann N Y Acad Sci. 2007; 1116: 29-49. (Pubitemid 350274336)
16. Guo X, Wang XF., Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009; 19: 71-88.
17. Chang L, Karin M., Mammalian MAP kinase signalling cascades. Nature. 2001; 410: 37-40. (Pubitemid 32225829)
18. Gallea S, Lallemand F, Atfi A, et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12cells. Bone. 2001; 28: 491-498. (Pubitemid 32410000)
19. Vinals F, Lopez-Rovira T, Rosa JL, Ventura F., Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett. 2002; 510: 99-104. (Pubitemid 34084891)
20. Celil AB, Campbell PG., BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem. 2005; 280: 31353-31359. (Pubitemid 41291875)
21. Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J., Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res. 2003; 18: 2060-2068. (Pubitemid 37377457)
22. Davis RJ., Signal transduction by the JNK group of MAP kinases. Cell. 2000; 103: 239-252.
23. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, Ohnishi T., JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J Bone Miner Res. 2009; 24: 398-410.
24. Lemonnier J, Ghayor C, Guicheux J, Caverzasio J., Protein kinase C-independent activation of protein kinase D is involved in BMP-2-induced activation of stress mitogen-activated protein kinases JNK and p38 and osteoblastic cell differentiation. J Biol Chem. 2004; 279: 259-264. (Pubitemid 38044823)
25. Wang D, Christensen K, Chawla K, Xiao G, Krebsbach PH, Franceschi RT., Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J Bone Miner Res. 1999; 14: 893-903. (Pubitemid 29262883)
26. Boden SD, McCuaig K, Hair G, et al. Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation in vitro. Endocrinology. 1996; 137: 3401-3407. (Pubitemid 26250191)
27. Okada M, Sangadala S, Liu Y, et al. Development and optimization of a cell-based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein-2 activity. Cell Biochem Funct. 2009; 27: 526-534.
28. Lei K, Nimnual A, Zong WX, et al. The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase. Mol Cell Biol. 2002; 22: 4929-4942. (Pubitemid 34620425)
29. Zanella JM, Oliver C, Peckham SM, McKay B, Toth JM, Boden SD., Effect on bone induction of using contrast media to reconstitute recombinant human bone morphogenetic protein-2 in an ectopic model in rats. J Neurosurg Spine. 2006; 5: 434-439. (Pubitemid 47325354)
30. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT., Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1cells. J Bone Miner Res. 2002; 17: 101-110. (Pubitemid 33151001)
31. Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N., Induction of osteoblast differentiation indices by statins in MC3T3-E1cells. J Cell Biochem. 2004; 92: 458-471.
32. Schindeler A, Little DG., Ras-MAPK signaling in osteogenic differentiation: friend or foe ? J Bone Miner Res. 2006; 21: 1331-1338. (Pubitemid 44300039)
33. Javelaud D, Mauviel A., Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene. 2005; 24: 5742-5750. (Pubitemid 43086134)
34. Kretzschmar M, Doody J, Massague J., Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature. 1997; 389: 618-622. (Pubitemid 27446181)
35. Wrighton KH, Feng XH., To (TGF)beta or not to (TGF)beta: fine-tuning of Smad signaling via post-translational modifications. Cell Signal. 2008; 20: 1579-1591.
36. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J., Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell. 2007; 25: 441-454. (Pubitemid 46199289)
37. Sapkota G, Knockaert M, Alarcon C, Montalvo E, Brivanlou AH, Massague J., Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem. 2006; 281: 40412-40419. (Pubitemid 46041844)